Usefulness of lysophosphatidylcholine measurement in the cerebrospinal fluid for differential diagnosis of neuropathic pain: possible introduction into clinical laboratory testing.

[1]  M. Sumitani,et al.  Different Profiles of the Triad of Lysophosphatidylcholine, Lysophosphatidic Acid, and Autotaxin in Patients with Neuropathic Pain Diseases: a Preliminary Observational Study , 2022, Pain and Therapy.

[2]  Sakae Tanaka,et al.  Diabetes is associated with greater leg pain and worse patient-reported outcomes at 1 year after lumbar spine surgery , 2021, Scientific Reports.

[3]  M. Sumitani,et al.  Inhibition of autotaxin activity ameliorates neuropathic pain derived from lumbar spinal canal stenosis , 2021, Scientific Reports.

[4]  H. Ueda.  LPA receptor signaling as a therapeutic target for radical treatment of neuropathic pain and fibromyalgia. , 2019, Pain management.

[5]  M. Sumitani,et al.  Alteration of the lysophosphatidic acid and its precursor lysophosphatidylcholine levels in spinal cord stenosis: A study using a rat cauda equina compression model , 2019, Scientific Reports.

[6]  B. Gerdle,et al.  CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia , 2019, Journal of pain research.

[7]  M. Kurano,et al.  Evaluation of Lysophospholipid Measurement in Cerebrospinal Fluid Samples using Liquid Chromatography-Tandem Mass Spectrometry. , 2019, Lipids.

[8]  Sakae Tanaka,et al.  Lysophosphatidic acids and their substrate lysophospholipids in cerebrospinal fluid as objective biomarkers for evaluating the severity of lumbar spinal stenosis , 2019, Scientific Reports.

[9]  M. Kurano,et al.  Lysophospholipids in laboratory medicine , 2018, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[10]  M. Sumitani,et al.  Lysophosphatidic acid is associated with neuropathic pain intensity in humans: An exploratory study , 2018, PloS one.

[11]  R. Baron,et al.  Diagnosis and assessment of neuropathic pain through questionnaires , 2018, The Lancet Neurology.

[12]  Blair H. Smith,et al.  Neuropathic pain: an updated grading system for research and clinical practice , 2016, Pain.

[13]  K. Lynch.  CLSI C62-A: A New Standard for Clinical Mass Spectrometry. , 2016, Clinical chemistry.

[14]  B. Gerdle,et al.  Multivariate proteomic analysis of the cerebrospinal fluid of patients with peripheral neuropathic pain and healthy controls – a hypothesis-generating pilot study , 2015, Journal of pain research.

[15]  H. Daida,et al.  Possible Involvement of Minor Lysophospholipids in the Increase in Plasma Lysophosphatidic Acid in Acute Coronary Syndrome , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[16]  Blair H. Smith,et al.  Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis , 2015, The Lancet Neurology.

[17]  E. Kalso,et al.  A new definition of neuropathic pain , 2011, PAIN®.

[18]  J. Aoki,et al.  LPA(3), a unique G protein-coupled receptor for lysophosphatidic acid. , 2010, Progress in lipid research.

[19]  Kozo Nakamura,et al.  Predictors of residual symptoms in lower extremities after decompression surgery on lumbar spinal stenosis , 2010, European Spine Journal.

[20]  H. Ueda,et al.  Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling , 2004, Nature Medicine.

[21]  Y. Soda,et al.  An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. , 2002, Clinical biochemistry.